ArticleScientific reports2024
Mesoporous silica nanoparticles co-loaded with lysozyme and vancomycin for synergistic antimicrobial action.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Smart Mesoporous Silica Nanoparticle-Based Drug Delivery Systems: Recent Advances in Biomedical Applications, Wound Healing and Therapeutic Perspectives.Pharmaceutics · 2026Review
- Antibacterial potential, DNA binding and molecular docking investigations of newly green synthesized zinc oxide/chitosan/vancomycin nanocomposite using Bacillus licheniformis ATCC 4527 against some drug-resistant bacteria.Microbial cell factories · 2026Article
- Antimicrobial Peptide-Loaded Mesoporous Silica Nanoparticles: A pH-Triggered Controlled Release against Biofilms.ACS omega · 2025Article
- The Impact of Scaling and Root Planing onArchives of Razi Institute · 2025Article
- Evaluation of combined BCG and SARS-CoV-2 vaccination for immune enhancement and lung protection in Syrian hamsters.Scientific reports · 2025Article
- Synergistic Antifungal Efficacy of Eugenol-Loaded Nanocapsules Combined With Itraconazole Against Trichophyton mentagrophytes.Veterinary medicine and science · 2025Article
- Antifungal potential of copper oxide nanoparticles againstCurrent medical mycology · 2025Article
- Antimicrobial Mechanisms of Metal-Based Nanomaterials.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanotechnology offers a novel strategy for enhancing the susceptibility of pathogens resistant to traditional antibiotics. Another effective strategy is combination therapy, where multiple agents are used together to improve treatment efficacy. In this study, both nanoparticle-based formulation and combinatorial therapy were utilized to develop a potent antibacterial system targeting infectious bacteria. Lysozyme (Lys) and Vancomycin (Van) were co-loaded onto mesoporous silica nanoparticles (MSNs), forming Lys-Van-MSNs. The antimicrobial activity of these nanoparticles was evaluated by determining the minimum inhibitory concentration (MIC) against Staphylococcus aureus. The MIC values for Lys-Van-MSNs were 0.85 µg/ml for Van and 0.168 mg/ml for Lys, reflecting reductions of 86.4% and 93.7%, respectively, compared to the free forms. Additionally, cytotoxicity was tested using MTT, ROS, and hemolysis assays on human cell lines (breast, fibroblast, and AGS), showing over 80% cell viability, indicating minimal toxicity. The MSN-based formulation, with its synergistic antibacterial effects, reduced drug dosage, and high biocompatibility, offers a practical and effective solution for addressing bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.